Can drug monitoring make a common lung cancer treatment safer and more effective?
NCT ID NCT06195527
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study is looking at whether regularly checking the amount of pembrolizumab in the blood of people with non-small cell lung cancer can help doctors tailor treatment. The goal is to see if this monitoring can improve how well the drug works and reduce side effects. The trial will enroll 75 adults already receiving pembrolizumab as part of their standard care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab
What this could lead to
If successful, this could help doctors personalize pembrolizumab dosing for lung cancer patients, potentially improving outcomes and reducing side effects.
What could go wrong
This is a small, early-phase observational study (75 participants) that does not test a new treatment. It may not find a clear link between drug levels and response, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Angers University Hospital
RECRUITINGAngers, 49000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CH Le Mans
NOT_YET_RECRUITINGLe Mans, 53000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••